Gapping down
In reaction to disappointing earnings/guidance:
- ACHC -22.3%, AMD -10.7%, CMG -10.6%, MANH -9.9%, GHM -8.5%, JNPR -6.7%, EW -6.3%, VICR -6.3%, DPS -5.1%, SFLY -3.6%, NBR -3.4%, EXP -3.3%, DFS -3.1%, WYN -2.3%, AMX -2.1%, T -2%, TXN -1.7%, OC -1.6%, ESRX -1.4%, ROL -1.1%
Other news:
- SNSS -13.5% (commences offering of common stock and Series D Convertible Preferred Stock)
- SVRA -11% (commences common stock offering; size not disclosed; anounces its indication expansion strategy of its lead product candidate Molgradex for the treatment of nontuberculous mycobacterial lung infection; plans to initiate a Phase 2a multi-center clinical trial in subjects with antibiotic-resistant NTM lung infection in early 2018)
- HCM -9.4% (to offer $262.0 million of ADS's, each representing one-half of one ordinary share )
- IDRA -8.7% ( commences $60 mln common stock offering)
- SALT -7.8% (commences 10 mln common stock offering )
- BIOA -6.5% (accepted the resignation of Pres/COO Fabrice Orecchioni; will be assuming advisory role through to February 24, 2018)
- SACH -6% (prices 3.75 mln common stock offering at $4.00/share)
- PFLT -4.5% (to make a public offering of 6,000,000 shares of its common stock )
- ATNM -4.1% ( indicated lower after filing for $200 mln mixed securities shelf offering and $75 mln ATM under 424B3)
- IMDZ -1.1% (prices 18.5 mln shares of common stock at $4.10 per share)
- NVDA -0.5% (following AMD results)
Analyst comments:
- RCII -5.3% (downgraded to Market Perform from Outperform at BMO Capital Markets)
- PII -1.7% (downgraded to Market Perform from Outperform at BMO Capital Markets)
- GM -1.7% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- HBI -1% (downgraded to Market Perform from Outperform at Wells Fargo)
- NVS -0.5% (downgraded to Underweight from Equal Weight at Barclays)